Chronic Myeloid Leukaemia Medications

50mg

Developed to manage chronic myeloid leukaemia; indicated to support effective leukaemia control.

100 · 400mg

designed to target cancer cells to alleviate disease progression.

500mg

Developed to alleviate conditions involving abnormal blood cell growth to address long-term stability and symptom control.

500mg

Formulated to target cancerous cell growth and indicated to support blood count regulation, this agent is utilized to manage specific haematologic conditions.

50mg

utilized to target kinase-positive leukaemias and formulated to support the mitigation of malignant cell growth in patients.

150 · 200mg

utilized to target specific protein kinases in chronic myeloid leukaemia and designed to alleviate disease progression in affected patients.